medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 3

<< Back Next >>

salud publica mex 2022; 64 (3)

Serological follow up of positive SARS-CoV-2 cases

González-González JG, Camacho-Ortiz A, Rodríguez-Gutiérrez R, Saldívar-Rodríguez D, Ramírez-García LA, Sánchez-García A

Language: English
References: 28
Page: 243-248
PDF size: 278.02 Kb.


ABSTRACT

Objective. To describe the humoral response in a cohort with mild and asymptomatic SARS-CoV-2 infection previously identified in a community-based serological survey. Materials and methods. This study was an observational follow up of 193 subjects previously identified with positive anti-SARS-CoV-2 antibodies invited for a second test 112 days after the first sampling. All completed a standardized electronic questionnaire. IgM/IgG antibodies were determined using a qualitative IgM/IgG chemiluminescent immunoassay. Results. Among the 193 eligible subjects, a total of 174 (90%) attended the follow-up visit, and their serum samples were tested. Of the samples, 171 (98.3%) were still positive, and 3 (1.7%) were negative. Also, the cut-off index (COI) value of the immunoassay significantly increased from the first to the second test (P ‹0.001). Conclusions. Our findings support a sustained humoral response in individuals with mild and asymptomatic SARS-CoV-2 infection up to 112 days after a positive serologic baseline test, accompanied by increasing antibody titers.


REFERENCES

  1. Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveysof anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314-22. https://doi.org/10.1016/j.ijid.2020.10.011

  2. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Shiadeh MN, EsfandyariS, et al. SARS-CoV-2 seroprevalence worldwide: a systematic reviewand meta-analysis. Clin Microbiol Infect. 2020;27(3):331-40. https://doi.org/10.1016/j.cmi.2020.10.020

  3. Murchu EO, Byrne P, Walsh KA, Carty PG, Conolly M, De Gascun C,et al. Immune response following infection with SARS-CoV-2 and othercoronaviruses: A rapid review. Rev Med Virol. 2021;31(2):e2162. https://doi.org/10.1002/rmv.2162

  4. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission,and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. https://doi.org/10.1136/bmj.m3862

  5. Moore JP, Offit PA. SARS-CoV-2 Vaccines and the growing threat of viralvariants. JAMA. 2021;325(9):821-2. https://doi.org/10.1001/jama.2021.1114

  6. Raman R, Patel KJ, Ranjan K. COVID-19: unmasking emerging SARSCoV-2 variants, vaccines and therapeutic strategies. Biomolecules.2021;11(7):993. https://doi.org/10.3390/biom11070993

  7. Kellam P, Barclay W. The dynamics of humoral immune responsesfollowing SARS-CoV-2 infection and the potential for reinfection. J GenVirol. 2020;101(8):791-7. https://doi.org/10.1099/jgv001439

  8. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistenceand decay of human antibody responses to the receptor bindingdomain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol.2020;5(52):eabe0367. https://doi.org10.1126/sciimmunol.abe0367

  9. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M,Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19patients and healthy volunteers up to 6 months post disease onset. Eur JImmunol. 2020;50(12):2025-40. https://doi.org/10.1002/eji.202048970

  10. Malfertheiner SF, Brandstetter S, Roth S, Harner S, Buntrock-DöpkeH, Toncheva AA, et al. Immune response to SARS-CoV-2 in health careworkers following a COVID-19 outbreak: A prospective longitudinal study.J Clin Virol. 2020;130:104575. https://doi.org/10.1016/j.jcv.2020.104575

  11. Marklund E, Leach S, Axelsson H, Nyström K, Norder H, BemarkM, et al. Serum-IgG responses to SARS-CoV-2 after mild and severeCOVID-19 infection and analysis of IgG non-responders. PLoS One.2020;15(10):e0241104. https://doi.org/10.1371/journal.pone.0241104

  12. Risch M, Weber M, Thiel S, Grossmann K, Wohlwend N, lung T, et al.Temporal course of SARS-CoV-2 antibody positivity in patients withCOVID-19 following the first clinical presentation. Biomed Res Int.2020;2020:9878453. https://doi.org/10.1155/2020/9878453

  13. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, etal. SARS-CoV-2 infection induces robust, neutralizing antibody responsesthat are stable for at least three months. MedRxiv [preprint]. 2020. https://doi.org/10.1101/2020.07.14.20151126

  14. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliot J, Hofmann C,Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in personswith mild Covid-19. N Engl J Med. 2020;383(11):1085-7. https://doi.org/10.1056/NEJMx200017

  15. Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, et al. Three-monthfollow-up study of survivors of coronavirus disease 2019 after discharge. JKorean Med. 2020;35(47):e418. https://doi.org/10.3346/jkms.2020.35.e418

  16. Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, et al.Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep.2020;10(1):20048. https://doi.org/10.1038/s41598-020-77125-8

  17. Moncunill G, Mayor A, Santano R, Jiménez A, Vidal M, Tortajada M, etal. SARS-CoV-2 seroprevalence and antibody kinetics among health careworkers in a Spanish hospital after three months of follow-up. J Infect Dis.2021;223(1):62-71. https://doi.org/10.1093/infdis/jiaa696

  18. Self WH, Tenforde MW, Stubblefield WB, Feldstein LR, Steingrub JS,Shapiro NI, et al. Decline in SARS-CoV-2 antibodies after mild infectionamong frontline health care personnel in a multistate hospital network -12 states, April-August 2020. Morb Mortal Wkly Rep. 2020;69(47):1762-6.https://doi.org/10.15585/mmwr.mm6947a2

  19. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel K, et al. Longitudinalobservation and decline of neutralizing antibody responses in thethree months following SARS-CoV-2 infection in humans. Nat Microbiol.

  20. 2020;5(12):1598-607. https://doi.org/10.1038/s41564-020-00813-820. Díaz-Salazar C, Sánchez-García A, Rodríguez-Gutiérrez R, Camacho-Ortiz A, Saldívar-Rodríguez D, González-González JG. Prevalence andassociated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5months after pandemic arrival. BMC Infect Dis. 2021;21(1):835. https://doi.org/10.1186/s12879-021-06550-5

  21. Chan CW, Parker K, Tesic V, Baldwin A, Tan NY, van Wijk X, et al.Analytical and clinical evaluation of the automated elecsys anti-SARSCoV-2 antibody assay on the Roche cobas e602 Analyzer. Am J Clin Pathol.2020;154(5):620-6. https://doi.org/10.1093/ajcp/aqaa155

  22. R Core Team. R: A language and environment for statistical computing.R Foundation for Statistical Computing. Vienna, Austria: R, 2020 [cited2021 Feb 12]. Available from: https://www.R-project.org/

  23. Sanchez A. Serological follow up of positive SARS-CoV-2 case:Supplementary Material 2022. figshare. Figures. https://doi.org/10.6084/m9.figshare.19651017.v1

  24. Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, CoughlinMM, Feldstein LR, et al. Change in antibodies to SARS-CoV-2 Over60 days among health care personnel in Nashville, Tennessee. JAMA.2020;324(17):1781-2. https://doi.org/10.1001/jama.2020.18796

  25. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical andimmunological assessment of asymptomatic SARS-CoV-2 infections.Nat Med. 2020;26(8):1200-4. https://doi.org/10.1038/s41591-020-0965-6

  26. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infectioninduces sustained humoral immune responses in convalescent patientsfollowing symptomatic COVID-19. Nat Commun. 2021;12(1):1813.https://doi.org/10.1038/s41467-021-22034-1

  27. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responsesand serological assays in SARS-CoV-2 infections. Front Immunol.2020;11:610688. https://doi.org/10.3389/fimmu.2020.610688

  28. Batra M, Tian R, Zhang C, Clarence E, Sacher CS, Miranda JN, et al. Roleof IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes.Sci Rep. 2021;11(1):3455. https://doi.org/10.1038/s41598-021-83108-0




2020     |     www.medigraphic.com